Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.

@article{Shin2006RecombinantUO,
  title={Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.},
  author={Hee Young Shin and Hyoung Jin Kang and Eun Sil Park and Hyoung Soo Choi and Hyo Seop Ahn and Sun Young Kim and Nak Gyun Chung and Hack Ki Kim and So Youn Kim and Hoon Kook and Tai J u Hwang and Kwang Chul Lee and Sun min Lee and Kun Soo Lee and Keon Hee Yoo and Hong Hoe Koo and Mee Jung Lee and Jong Jin Seo and Hyung Nam Moon and Thad T. Ghim and Chuhl Joo Lyu and Won Sik Lee and Yong Mook Choi},
  journal={Pediatric blood & cancer},
  year={2006},
  volume={46 4},
  pages={
          439-45
        }
}
BACKGROUND Hyperuricemia accompanying tumor lysis syndrome is a serious complication in neoplasia with rapid proliferation and destruction. To confirm the efficacy of recombinant urate oxidase (rasburicase) and its safety profile, a phase IV compassionate use prospective study was performed in Korean pediatric patients with hematologic malignancies. PROCEDURE Rasburicase was administered at 0.2 mg/kg/day once daily for 3-5 days (twice daily allowed during the first 72 hr) by intravenous route… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…